Peregrine Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, announced that it has submitted a phase II clinical protocol with the Ministry of Health of the Republic of Georgia to study bavituximab in combination with the chemotherapy drug docetaxel in patients with metastatic breast cancer. The open label, multi-centre safety and efficacy trial will begin enrolling patients pending regulatory and ethics committee approvals.
The new trial has a two-stage design. Up to 15 patients with metastatic breast cancer will be enrolled initially and the study will be expanded up to a total of 46 patients if promising results are observed in the first cohort. The primary objective is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in the treatment for metastatic breast cancer. Secondary objectives include measuring time to tumour progression, duration of response, overall patient survival and safety parameters. The study is expected to enroll patients at a minimum of three clinical trial sites.
"The filing of this second breast cancer protocol continues our strategy of evaluating bavituximab in phase II combination studies in specific cancer indications. This study also marks our first clinical initiative in Eastern Europe, which has become a major venue for global clinical trials conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards. The sites we are working with have solid experience in conducting mid and late stage cancer trials that adhere to FDA and international standards. We have been impressed to date by the professionalism of their operations, the efficiency of their patient recruitment infrastructure and their commitment to patient welfare," said Steven W. King, president and CEO, Peregrine.
Tumour response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumours (RECIST) parameters. The trial is being conducted according to ICH and GCP guidelines.
According to the World Health Organisation, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 US women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.
Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumours, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumour growth and spread. In a phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50 per cent of the evaluable patients. A protocol for a phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a phase II trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is also under regulatory review in India. Bavituximab is in clinical trials in the US in patients with advanced solid tumours and in patients co-infected with HCV and HIV.
Peregrine Pharmaceuticals is a biopharmaceutical company with a portfolio of innovative clinical stage and preclinical product candidates for the treatment of cancer and viral diseases. Bavituximab anti-viral is in phase I studies for hepatitis C infection and pre-clinical studies in influenza and other life-threatening viral infections and bavituximab anti-cancer is in a phase I trial for solid tumour cancers.